Published in J Am Coll Cardiol on October 21, 2014
Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J (2016) 0.87
High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation (2015) 0.86
Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study). Am J Cardiol (2015) 0.80
Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol (2016) 0.78
N-terminal pro-B-type natriuretic peptide: a risk predictor for all. J Am Coll Cardiol (2014) 0.77
Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. Am J Cardiol (2015) 0.77
Retinopathy Signs Improved Prediction and Reclassification of Cardiovascular Disease Risk in Diabetes: A prospective cohort study. Sci Rep (2017) 0.75
A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts. Circulation (2017) 0.75
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med (2008) 7.33
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA (2012) 6.29
Lifetime risks of cardiovascular disease. N Engl J Med (2012) 5.95
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
Robust variance estimation for the case-cohort design. Biometrics (1994) 5.03
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
Impact of obesity on plasma natriuretic peptide levels. Circulation (2004) 4.46
The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol (2005) 3.85
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med (2005) 3.35
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation (2010) 2.84
PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol (2013) 2.83
Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation (2005) 2.47
Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med (2010) 2.43
B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation (2009) 2.37
The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study. J Am Coll Cardiol (2012) 2.22
Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol (2002) 2.13
Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation (2012) 1.95
Computing the Cox model for case cohort designs. Lifetime Data Anal (1999) 1.85
Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke (2013) 1.47
Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J (2011) 1.42
N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J (2007) 1.30
Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol (2004) 1.23
Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study. Atherosclerosis (2009) 0.99
Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur Heart J (2006) 0.98
Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study. Circulation (2011) 0.96
Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail (2006) 0.94
Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem (2013) 0.88